Publication
Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer.
M Chiappa, V Villa, F Sias, C Grasselli, L Sala, S Canesi, M Marabese, S Mason, D Dibitetto, R Fruscio, G Damia
Experimental hematology & oncologySep 15, 2026PMID 42745296doi:10.1186/s40164-026-00828-7 PMC13579897LetterpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
High-grade serous ovarian carcinoma (HGSOC) often shows an initial response to poly (ADP-ribose) polymerase inhibitors (PARPi) such as olaparib, particularly in tumors with defects in homologous recombination (HR), but resistance to these drugs is a major clinical challenge. To address this, we…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.